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Abstract
Upper Aero digestive Tract (UADT) is the commonest site for the development of second cancer
in females after primary cervical cancer. Glutathione S-transferase (GSTM1 and / or T1) null
genotype modulates the risk of developing UADT cancer (primary as well as second cancer). The
aim of this study was to evaluate the difference in GST null genotype frequencies in females with
paired cancers in the UADT and genital region as compared to females with paired cancers in the
UADT and non-genital region. Forty-nine females with a cancer in the UADT and another cancer
(at all sites-genital and non-genital) were identified from a database of patients with multiple
primary neoplasms and were analyzed for the GSTM1 and T1 genotype in addition to known factors
such as age, tobacco habits, alcohol habits and family history of cancer. Frequencies of GSTM1 null,
GSTT1 null, and either GSTM1/T1 null were higher in females with paired occurrence of cancer in
the UADT and genital site (54%, 33% and 75% respectively) in comparison to females with paired
occurrence of cancer in the UADT and non-genital sites (22%, 6% and 24% respectively). The
significantly higher inherited frequency of either GSTM1/T1 null genotype in females with a paired
occurrence of cancers in UADT and genital region (p = 0.01), suggests that these females are more
susceptible to damage by carcinogens as compared to females who have UADT cancers in
association with cancers at non-genital sites.
Introduction
Precise risk estimation for the development of second can-
cers in the Head & Neck, Lung, and Esophagus, also
known as the Upper Aero-Digestive Tract (UADT), is
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difficult due to the multifactorial origin and gene-envi-
ronment interaction [1].
The Glutathione S transferase (GST) family of enzymes
coded for by at least five distinct loci-alpha, mu, theta, pi
and gamma detoxify tobacco carcinogens [2] and play an
important role in the gene-environment interaction asso-
ciated risk for cancer. The results of a recently published
meta- and pooled- analysis of 4635 cases and 5770 con-
trols, support the widely studied association of inherited
GST genotype with the risk of developing squamous cell
carcinomas (SCC) in the UADT. In addition the results
support the notion that the risk increases when genotypes
at multiple GST loci are considered [3]. Patients with sec-
ond (synchronous and metachronous) cancers in the
UADT also have a higher frequency of GST null genotype
(particularly GSTM1 and T1) as compared to those with
single cancers [4-7].
Similar to the association seen in UADT cancers, GST null
genotype has been associated with the risk of developing
Human Papilloma Virus (HPV)-positive primary cervical
cancer in females [8,9] and also with other cancers such as
primary breast cancer [10] and primary thyroid cancer
[11].
Females with a primary HPV related cancer (particularly
uterine cervix) develop second cancers in the UADT with
an increased frequency [12-14]. HPV transmission has
been suggested to account in part for the paired occur-
rence of cancers at these anatomically distinct sites of
UADT and cervix. Exposure to tobacco carcinogens has
been suggested as synergistic cofactor [15,16]. The mech-
anism by which HPV infection, necessary for the develop-
ment of cervical cancer [17], causes UADT cancers is
unclear [18]. Recently it has been shown that interaction
between viral infection (especially HPV) and xenobiotic
enzymes such as GSTM1  could modulate cancer risk,
however the evidence comes from in vitro studies alone
[19].
There are no studies found in the literature evaluating the
association of GST null genotypes and the risk of develop-
ing second cancers in the UADT in females, particularly
after primary cancers at genital sites. We identified females
with a paired cancer in the UADT in association with
another cancer (at all sites-genital and non-genital) and
analyzed GSTM1 and T1 genotype in addition to known
factors such as age, tobacco habits, alcohol habits and
family history of cancer.
Patients and methods
Patients
From a registry of 150 patients with Multiple Primary
Neoplasms (MPN) at Tata Memorial Hospital, Mumbai,
during the period of 1996 – 2004, all the females, who
met the following criteria were selected: 1) synchronous
or metachronous occurrence of second primary cancer; 2)
Histological or cytological confirmation of both prima-
ries; 3) One of the two cancers was a SCC in the UADT.
Modified Hong's criteria [20] was used to differentiate the
second primary cancer from metastatic or direct spread
from the first cancer.
Details about age, site of first cancer, site of second cancer,
histology, grade, history of cancer in the first degree rela-
tives, tobacco habits (smoking or smokeless), alcohol
intake (regular, occasional or never) and radiotherapy for
the first cancer were noted both from patient interviews
and medical records. Detailed and exact quantification of
exposure to tobacco and alcohol was not available in all
cases. Neither were details about reproductive and sexual
history available.
DNA extraction
Having obtained an informed consent, 5–10 ml of
peripheral blood sample was collected in sterile EDTA
tubes. The DNA was extracted from the leukocyte pellet
obtained from the blood by sucrose lysis, purified by phe-
nol: chloroform and suspended in Tris-EDTA buffer and
stored at -20°c.
PCR
Multiplex Polymerase Chain reaction (PCR) was per-
formed to simultaneously genotype GSTM1  or  GSTT1
gene and the Human Fibroblast Interferonβ -1 gene (IFNβ -
1). The IFNβ -1 gene was used as an internal control for
amplification failure. The primer sequences were as
follows
1) GSTM1: F: 5' CTG GAT TGT AGC AGA TCA TGC 3' and
R: 5' CTG CCC TAC TTG ATT GAT GGG 3' which generates
a 273 bp fragment;
2) GSTT1: F: 5' TTC CTT ACT GGT CCT CAC ATC TC 3'
and R: 5' TCA CCG GAT CAT GGC CAG CA 3' which gen-
erates a 459 bp fragment and
3) IFNβ -1: F: 5' GGC ACA ACA GGT AGT AGG CG 3' and
R: 5' GCC ACA GGA GCT TCT GAC AC 3' which generates
a 170 bp fragment.
The GSTM1 or GSTT1 gene and Interferon gene were co-
amplified in a 15 µl reaction mixture containing a total of
50 ng of genomic DNA as the template, 2.6 µM of each
GSTM1 primer, or 2.6 µM of each GSTT1 primer, and 2.6
µM of each Interferon primer, 1.2 mM each dNTP, 1 ×
PCR buffer (which contained 20 mM Tris, pH 8.4, 50 mM
KCl), 2 mM MgCl2 and 0.6 units of Taq polymerase
(Amersham). The PCR profile for amplification of GSTM1Journal of Carcinogenesis 2005, 4:6 http://www.biomedcentral.com/1477-3163/4/6
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gene consisted of an initial melting step at 94°C for 9 min
followed by 30 cycles at 94°C for 1 min, 55°C for 1 min,
and 72°C for 1 min, with a final step at 72°C for 10 min
for elongation. The PCR profile for amplification of
GSTT1 gene consisted of an initial melting step at 95°C
for 9 min followed by 30 cycles at 94°C for 1 min, 66°C
for 1 min, and 72°C for 1 min, with a final step at 72°C
for 10 min for elongation.
Gel electrophoresis
The PCR products were separated either on 2% agarose
gels or on 12% polyacrylamide gels and were seen by
ethidium bromide staining or silver staining respectively.
In the PCR reaction presence of a 170 bp (IFNβ -1) band
alone and absence of a higher 273 bp (GSTM1) or 459 bp
(GSTT1) band indicated null genotype of the sample. In
the PCR assay when both Interferon and GST fragments
were absent then it indicated that either the PCR was not
successful or the DNA was degraded.
Statistical analysis
Fishers exact test was used to assess the statistical signifi-
cance for the difference between proportions of various
factors (number of tobacco chewers, GSTM1 null, GSTT1
null, either GSTM1/T1 null).
Results
Overall data of all females
Forty-nine females with a paired SCC in the UADT in
association with another cancer (at genital and non-geni-
tal related sites) were identified. The median time to
development of the paired cancer (or second cancer) was
4 years. The median age at diagnosis of first cancer in all
females was 51 years and that of second cancer was 60
years. The commonest sites of first cancer were oral cavity
(n = 17), genital region (n = 15), and esophagus including
post-cricoid region (n = 12). Information on family his-
tory of cancer was available in 42 women and 6 (14.3%)
had a first-degree relative affected with cancer. Of the 45
women where details of habits were available, 25 (56%)
were tobacco chewers whereas only 1 (2%) smoked. Of
the 29 patients in whom GSTM1 and T1 genotyping was
done, the frequencies of GSTM1 null, GSTT1 null and
either  GSTM1/T1  null were 35%, 17% and 45%
respectively.
Groupwise analysis
Results were further analyzed by dividing the females into
two Groups (Table 1): Group 1 (n = 19), females who had
a paired SCC in the UADT along with a cancer in the gen-
ital region and Group 2 (n = 30), females who had a
paired SCC in the UADT along with a cancer at other sites
(non-genital region). In the majority of the cases (80% in
Group 1 and 86% in Group 2), UADT cancer occurred sec-
ond in chronological order. The median time for the
development of second cancer was 5-years (range 0–20
years) for females in Group 1 in comparison to 3-years
(range 0–24 years) for females in Group 2. There were no
significant differences in the median age at the diagnosis
of the first cancer, family history of cancer or tobacco hab-
its between the two groups. Uterine cervix was the com-
monest genital site of cancer in females in Group 1 (16/
19, 84%), followed by vagina in one female, vaginal vault
in one and vulva in one. The sites of second UADT cancer
in females in Group 1 were: oral cavity (n = 7), orophar-
ynx (n = 2), hypo pharynx (n = 1), trachea and Lung (n =
4), esophagus including post-cricoid (n = 4), thyroid (n =
1). In the females in Group 2, UADT was the commonest
non-genital site of cancer (22/30, 73%), followed by
breast (n = 6), duodenum (n = 1), and chronic lymphatic
leukemia (n = 1). Histology of the cancer in the genital
region in females in Group 1 was confirmed as SCC in the
majority (18/19). In the remaining female the histology
could not be confirmed as the records were missing, how-
ever it was confirmed that her cervical cancer was treated
with radiotherapy, a treatment that is never given without
histological confirmation at our hospital.
Table 1: Comparison of host, environment and treatment related parameters in the two Groups of females with second cancer in the 
UADT.
Group 1 [n = 19] Group 2 [n = 30] p value
Median age at the diagnosis of first cancer [years] 50 53 0.58
Median time to development of second cancer in years [range] 5 [range 0–20 years] 3 [range 0–24 years] 0.31
Family history of cancer 3/18 3/24 1.00
GSTM1 null 7/13 [54%] 4/18 [22%] 0.12
GSTT1 null 4/12 [33%] 1/17 [6%] 0.13
Either GSTM1/T1 null 9/12 [75%] 4/17 [24%] 0.01
*Tobacco habits 9/18 [50%] 17/27 [63%] 0.54
* Except one smoker, all other habitués were tobacco chewers and none of them consumed alcohol.Journal of Carcinogenesis 2005, 4:6 http://www.biomedcentral.com/1477-3163/4/6
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Null genotype frequencies for GSTT1, GSTM1 and either
T1 or M1 were more frequent in Group 1 as compared to
Group 2. The proportion of females who were null for
either GSTM1/T1 were found to be significantly higher in
the Group 1 than in Group 2.
Discussion
This is the first study evaluating the association of GST
genotype with paired occurrence of an UADT cancer and
genital site cancer. Of the 49 women with paired occur-
rence of an UADT SCC with a second cancer at any site, 19
(39%) were in the HPV related genital site. Majority
(84%) of the genital cancers were in the Uterine Cervix
and in more than half (68%) the genital cancer occurred
before or within 6 months of development of the UADT
cancer. Association between malignancies of the UADT
and genital region (especially uterine cervix) has been
observed by various investigators [13,15]. Hemminki et al
[14] studied the pattern of second cancers in females and
found a consistent increase in second HPV related cancer
when the first cancer was at an HPV related site (anogeni-
tal, skin, head and neck, oesophageal and rectal cancers).
An excess of oral cancers (including lip, mouth, tongue,
larynx and pharynx), as found in this study, followed cer-
vical cancers. Other investigators have also found similar
results in the past [12]. Using incidence data from Surveil-
lance, Epidemiology & End Results (SEER), Spitz et al [15]
found an elevated Standardized Incidence Ratio (SIR) for
cervical cancer after an initial buccal cavity cancer and lar-
ynx cancer.
HPV transmission has been suggested to account in part
for the paired occurrence of cancers at these anatomically
distinct sites of UADT and cervix and smoking has been
suggested as synergistic cofactor [15]. However, smokeless
tobacco is a predominant form of tobacco consumed by
females in India [21] and a recent study from India has
shown a positive correlation of smokeless tobacco habits
with cervical cancer risk [22]. Additionally, results from
another study from India found more than 80% of oral
cancers in females attributable to smokeless tobacco habit
as compared to the negligible influence of smoking and
drinking on oral cancer in females [23]. In concordance
with these figures, 44% of females in Group 1 in our study
had smokeless tobacco habits and none of the patients,
except for one, smoked.
The role of GST polymorphisms in the development of
second cancers in the UADT has been a focus of few stud-
ies in various ethnic groups [4-7]. In all of these studies
the GST null genotype (GSTM1 and or GSTT1) has been
seen with increased frequency in patients with second
cancers in the UADT as compared to those with single can-
cers in the UADT. The results of the recently published
meta and pooled analysis support the notion of a greater
risk of head and neck cancer when genotypes at multiple
GST loci are considered [3]. The 35% GSTM1 null geno-
type frequency (in entire population of females with sec-
ond cancers in the UADT) in this study is very similar to
the GSTM1 null genotype frequency of 36% found in our
previous study in male patients with second cancers in the
UADT from similar ethnic background [7]. However, the
null genotype frequency for GSTT1 in males was 41% vs.
17% in females from this study. Differences in the site of
cancer and the form of tobacco use, which predisposes to
cancer development at a particular site, between males
and females might possibly explain the gender discord-
ance in GSTT1 null genotype frequencies. Nonetheless the
41% and 17% null genotype frequency for GSTT1  in
males and females respectively are higher than 8–12%
GSTT1 null genotype frequency found in healthy controls
from similar ethnicity suggesting a true association
[24,25].
GSTM1 and GSTT1 null genotype frequencies (54% and
33%) in the females who had second cancer in the UADT
in association with a cancer in the genital region (Group
1) in the present study are higher than a) the respective
frequencies (22% & 6%) in females with second cancer in
the UADT in association with a cancer at non-genital
region (Group 2), b) the respective frequencies (49% &
18%) found in subjects with single UADT cancers in two
studies from a similar ethnic background [24,25], c) the
respective frequencies (26% & 19%) found in males with
single UADT cancers from our previous study [7], and d)
the respective frequencies (33% & 8% and 24% & 12%)
found in Indian healthy controls [24,25]. This suggests
that the females who developed second cancers in the
UADT in association with cancer at genital sites (Group 1
in this study) are possibly more susceptible to damage
induced by carcinogens.
The association of GST polymorphism and the risk of sin-
gle primary cervical SCC have been studied in female
patients from various ethnicities. GSTM1 null genotype
has been found to incur an increased risk for primary cer-
vical cancer in a mixed Caucasian, Hispanic and African-
American patient population as compared to controls [9].
Like wise, in a study on 181 Korean cervical carcinoma
patients, Kim et al [8], showed a positive correlation
between GST  genotypes and cervical carcinoma risk as
compared to controls. In this study by Kim et al, GSTT1
null genotype was associated with an increased risk for
cervical cancer. When the patients were stratified accord-
ing to age, either GSTM1/T1 null genotype was signifi-
cantly over represented in patients with cervical
carcinoma who were = 40 years old. However, in a study
on 190 Caucasian women, Chen et al [26], determined no
association of GSTM1 null genotype with invasive cervical
cancer risk. Other investigators have found results similarJournal of Carcinogenesis 2005, 4:6 http://www.biomedcentral.com/1477-3163/4/6
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to that found in the study by Chen et al [26-28]. Differ-
ences in GST genotype frequencies in various control pop-
ulations could account for the differences seen in various
studies. For instance, the prevalence of GSTM1 null geno-
type in Caucasian, American and Korean population is
similar (as high as 50%) whereas the prevalence of GSTT1
null genotypes varies from 15–31% in the Caucasians to
50–58% in the Koreans and Chinese.
In view of the known differences of the population fre-
quency of null genotypes and its associated risks for cervi-
cal cancer across various ethnic groups, it is important to
compare our results with those from studies conducted on
subjects from a similar ethnic background. GSTM1 and
GSTT1 null genotype frequencies (54% and 33% respec-
tively) in the females who had at least one of the cancers
in the genital region (Group 1) in the present study were
similar to the respective frequencies (57% and 20%
respectively) found in females with single (unpaired) cer-
vical cancer cases from India [29] suggesting that the asso-
ciation between GST genotype and cervical cancer risk in
Group 1 females in our study is more likely to be a true
association.
HPV is undoubtedly the main causative agent in cervical
SCC's and the prevalence of HPV, mainly HPV16/18 of
more than 95%, has been seen in tumours from cervical
cancer patients from India [30]. Evidence linking HPV to
oral carcinogenesis is also growing and one of the highest
prevalence rates of 74% of HPV 16 and 18 in oral tumors
from smokeless tobacco habitués have been reported
from southern India [31]. As HPV infections are transient,
the absence of HPV DNA does not rule out previous expo-
sure [32]. Interestingly, though most of the patients with
cervical cancer are positive for HPV [17], not all patients
who have HPV infection will go on to develop cancer [33].
Interactions between HPV and GST genotype may be a
reason for this. The evidence for this is two-way. Chen et
al [19] evaluating the reason for the lack of association
between GSTM1 null genotypes and cervical cancer risk in
their epidemiological study demonstrated that viral infec-
tion could have potential effect on the activity of xenobi-
otic metabolizing enzymes, particularly GSTM1. The
results of their study raised a question of how chronic viral
infections could affect cellular defenses against carcino-
gens in general. Evidence from other studies suggests that
inherited susceptibility in the form of GST genotype may
modulate the risk of developing HPV related cancer as evi-
denced by GSTM1 null genotype which, in addition to
HPV infection and smoking, has been found to increase
the risk of developing cervical cancer [9]. Moreover, in the
patients with cervix cancers having a positive association
with GST null genotype, as studied by Kim et al [8], HPV
16 or 18 infections were confirmed in all.
Conclusion
The findings of our study suggest an association between
the GST null genotype and the occurrence of paired can-
cers in the UADT and HPV related genital sites in females.
Though this is the first study to report such an association,
further confirmation from larger studies on patients from
different ethnic backgrounds is required.
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